GRTS - Despite The Fall Gritstone Oncology Phase 1 Results Reveal The Efficacy Signal I've Been Looking For

Like most small cap biotech investors I’m always looking for stocks that sell off following early phase clinical trial results although an efficacy signal is present and investment thesis intact. It is not surprising that these sell-the-news events occur as short term biotech traders jump in and out of stocks as catalysts approach. The recent Phase 1 clinical trial results released last week by clinical stage immune-oncology company Gritstone Oncology (GRTS) showed a similar pattern. The stock increased close to 25% from $6.50 to $8 in anticipation of their presentation of Phase 1 data for